News | Prostate Cancer | March 17, 2016

New research finds improvement in overall survival rates among men with aggressive prostate cancer who were treated with radiation at a facility that frequently performs that treatment

high-risk prostate cancer, radiation therapy, high volume facilities, Brigham and Women's Hospital study

March 17, 2016 — New research finds improvement in overall survival rates among men with aggressive prostate cancer who were treated with radiation at a facility that frequently performs that treatment.

In a new study led by researchers at Brigham and Women's Hospital, investigators looked at men with aggressive prostate cancer who were treated with radiation as well as the case volume of the facility at which they were treated. They found that receiving radiation at a facility that treats a high volume of prostate cancer patients with radiation was associated with improved overall survival.

These findings are published online and appear in the March 15, 2016 issue of the International Journal of Radiation Oncology, Biology, and Physics.

While it is well established that hospital volume and surgeon volume are associated with better outcomes for patients who require surgery for their cancer, relatively little is known about whether this positive association is also true for cancer patients who require radiation treatment.

"Our paper shows that experience counts," said Paul Nguyen, M.D., a physician researcher in the Department of Radiation Oncology at Brigham and Women's Hospital and corresponding author of the new paper. "For men with aggressive prostate cancer, survival is improved if they receive their radiation treatments at a high volume facility as opposed to a lower volume facility."

Using a large cancer database, researchers analyzed data from 19,565 high-risk prostate cancer patients who were treated with radiation at 1,099 facilities. This study focused on high-risk prostate cancer because these patients are much more likely to die from their disease than men with low- or intermediate-risk disease. After adjusting for stage of the disease, age, race, insurance status and other patient factors, researchers found that patients who received radiation at higher-volume facilities consistently had better survival rates than those treated at lower-volume facilities. For example, patients treated at a facility in the top 20 percent by prostate radiation volume (>43 patients per year) versus bottom 80 percent achieved a 76 percent versus 74 percent seven-year overall survival.

"We know that a surgeon who does a high volume of a specific procedure has better outcomes, and now we see that same trend when it comes to radiation therapy," Nguyen said. "At a higher volume facility, not only will the radiation oncologist have more experience at designing and delivering the appropriate treatment fields, but the multidisciplinary team of pathologists, radiologists, urologists and medical oncologists will have greater expertise in making accurate diagnoses and tailoring the systemic therapy regimen to ensure the best-possible outcome for the patient."

Researchers note that the study was observational, and while they adjusted for every known patient-related, socioeconomic and tumor-related factor available in the database, it is still possible that other factors that could not be fully controlled for are contributing to the outcomes observed. Future studies in other datasets are being planned to corroborate the strong effect seen here.

This research was funded by the Prostate Cancer Foundation, Fitz's Cancer Warriors, David and Cynthia Chapin, Hugh Simons in Honor of Frank and Anne Simons, Scott Forbes and Gina Ventre Fund, Jeffrey Campbell in Honor of Joan Campbell, and a grant from an anonymous family foundation.

For more information: www.redjournal.org


Related Content

News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
Subscribe Now